Sp1 is over-expressed in nasopharyngeal cancer and is a poor prognostic indicator for patients receiving radiotherapy

Jun Wang*, Min Kang*, Yu-Tao Qin, Zhu-Xin Wei, Jing-Jian Xiao, Ren-Sheng Wang

Department of Radiotherapy, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi, P.R. China. *Equal contributors.

Received April 3, 2015; Accepted May 19, 2015; Epub June 1, 2015; Published June 15, 2015

Abstract: Nasopharyngeal cancer (NPC) is a tumor of epithelial origin with complex etiology. Currently the standard treatment of NPC is radiotherapy, but therapy failure is quite common, making radioresistance an important issue. This study explores the association of specificity protein 1 (Sp1) protein expression with clinicopathological significance and disease prognosis in NPC patients receiving radiotherapy. A total of 82 NPC patients (55 males and 27 females, median age: 48 years old) were enrolled and received radiotherapy between September 2011 and March 2014. Tumor tissue and grossly adjacent normal mucosa were obtained in each patient. Sp1 expression was detected by western blot and immunohistochemical analysis, and the associations with clinicopathological status and radiotherapy response were analyzed. Our results showed Sp1 protein expression was higher in CNE-1 and CNE-2 nasopharyngeal cancer cells than in normal nasopharyngeal mucosal NP69 cells. All 82 patients’ tissue sections were stained positive for the Sp1 protein, and 39 (47.6%) patients showed higher level than adjacent normal mucosa. Sp1 overexpression in the tumor tissue was correlated with a higher tumor stage, nodal status, clinical stage and distant metastasis (P < 0.01). Patients with higher Sp1 expression in pretreatment biopsies had a lower radiotherapy response compared to those with lower expression. In conclusion, Sp1 may play roles in radioresistance of nasopharyngeal cancer which attributes to tumor invasiveness, and serve as a novel prognostic marker of NPC radiotherapy. However, further studies are required to validate our findings in larger samples and explore more detailed mechanisms underlying radioresistance of Sp1.

Keywords: Nasopharyngeal cancer (NPC), specificity protein 1 (Sp1), Epstein-Barr virus (EBV), prognosis, radioresistance

Introduction

Nasopharyngeal cancer (NPC) is one epithelial tumor originated from pharyngeal recess of the nasopharynx, with a special world distribution and complex etiology. Epidemiological studies have shown strong associations between nasopharyngeal cancer and genetic susceptibility, Epstein-Barr virus (EBV) infection, environmental factors and dietary carcinogens [1]. More than 80% of nasopharyngeal cancer patients are from Southern China and Southeast Asia, however, this cancer is rare in America, Europe and other parts of the world [2]. The standard treatment for nasopharyngeal cancer is radiotherapy [3]. Nasopharyngeal cancer is highly radiosensitive and chemosensitive in the early stages [4]. However, it is usually resistance to these treatment modalities in the more advanced stages [5]. Therefore, in locally advanced nasopharyngeal cancer, radiotherapy is usually integrated with the chemotherapeutic drug cisplatin in combination with fluorouracil [6, 7]. Although the radiotherapy technology and equipment are improved continually, the prognosis of locally advanced nasopharyngeal cancer is still very poor, with a low 5 year survival rate [8]. Radioresistance still remains the reason for treatment failure of many nasopharyngeal cancer patients. Therefore, it is very important to differentiate these radioresistant patients before therapy for judging the prognosis and optimization of individual treatment [9].

In order to better understand the mechanism of therapy resistance and prediction of radiothera-
Sp1 expression in nasopharyngeal cancer

The py effect, a lot of studies have been focused on the specifically expressed proteins in nasopharyngeal cancer. Epstein-Barr virus gene BHRF1 can inhibit nasopharyngeal cancer cellular apoptosis caused by radiation, contributing to fast recovery of cells after the radiation [10]. Another EB virus-encoded protein latent membrane protein 1 (LMP1) also contribute to radioresistance in nasopharyngeal cancer by suppressing the p53-mediated apoptosis pathway [11]. Leukemia inhibitory factor (LIF), whose production can be enhanced by LMP1, promotes nasopharyngeal cancer progression and radioresistance [12]. The radioresistance of nasopharyngeal cancer is also related with enhanced expression of antioxidant enzyme manganese superoxide dismutase (SOD2), 14-3-3 σ and Raf kinase inhibitory protein (RKIP) [13-15].

Specificity protein 1 (Sp1) protein is one member of transcription factor family and can bind GC/GT-rich promoter elements through its C(2) H(2)-type zinc fingers at C-terminal domains. Through either activating or repressing the activity of gene promoters, Sp1 protein regulates expression of multiple genes involved in differentiation, cell cycle and oncogenesis [16]. Growing evidence indicates that Sp1 protein play a critical role in many tumor types by regulating expression the growth and metastasis genes [17]. Over-expression of Sp1 can upregulate ABCG2 expression in lung cancer cells, which is a member of the ATP binding cassette (ABC) transmembrane proteins that plays an important role in chemotherapeutic resistance of cancer cells [18]. However, there are no investigations focused on radioresistance of Sp1 in nasopharyngeal cancer.

Hence, this study aimed to evaluate the expression of Sp1 in nasopharyngeal cancer cell lines and tissue samples at protein levels by western blot and immunohistochemistry. We also analyzed the correlation of Sp1 protein expression with clinicopathological parameters and radiotherapy response of nasopharyngeal cancer patients.

Materials and methods

Cell culture

Nasopharyngeal cancer cell lines CNE-1 and CNE-2 were routinely maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum (Hyclone), 2 mM sodium pyruvate, 2 mM penicillin-streptomycin L-glutamine (Invitrogen) and 2 mM minimum essential media non-essential amino acids solution (Invitrogen). Normal nasopharyngeal mucosal NP69 cells were cultured in RPMI-1640 supplemented with 10% FBS, 100 U/ml penicillin and 100 mg/ml streptomycin (Invitrogen). All cell lines were grown in a humidified atmosphere of 5% CO2 at 37°C.

Patients and specimens

This study consisted of 82 patients with nasopharyngeal cancer (55 males and 27 females), and the age of the patients ranged from 30 to 75, with a median age of 48 years old. All these patients were diagnosed with nasopharyngeal cancer by computed tomography (CT) or magnetic resonance imaging (MRI), who underwent treatment between September 2011 and March 2014, at the Affiliated Hospital of Guangxi Medical University (Nanning, China). Distant metastases were detected by a chest X-ray, liver ultrasound and bone scan. The nasopharyngeal cancer tissue and adjacent tissue were obtained from pretreatment endoscopic biopsies of patients, and formalin-fixed, paraffin-embedded tissues were cut to acquire biopsy sections at a thickness of 4 mm and mounted on 3-aminopropyl-tri-ethoxysilane (APES) slides. All 82 nasopharyngeal cancer patients were treated with radiotherapy and 67 patients received concurrent chemotherapy using the cytotoxic drugs (cisplatin and 5-fluorouracil). Complete response (CR, radiosensitive) NPC was defined as no local recurrence after radiotherapy for 2 month, with no local residual disease 6 weeks after treatment. Non-CR (radioresistant) patients was defined as lesions without complete regression of 6 weeks after treatment or longer, or with recurrence after 2 months after treatment, including partial response (PR), no change (NC) and progressive disease (PD). We acquired from all study subjects with written informed consent in accordance with the Declaration of Helsinki, and the study was approved by the Guangxi Medical University Research Ethics Committee.

Western blot analysis

Proteins from nasopharyngeal cancer cell lines or tissues were extracted using cell lysis buffer
Sp1 expression in nasopharyngeal cancer

Table 1. Association between Sp1 expression and clinicopathological parameters in nasopharyngeal carcinoma patients

<table>
<thead>
<tr>
<th>Sp1 expression level</th>
<th>All cases</th>
<th>Low expression</th>
<th>High expression</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>44</td>
<td>23 (53.5%)</td>
<td>22 (56.4%)</td>
<td>0.182</td>
</tr>
<tr>
<td>≥ 50 year*</td>
<td>38</td>
<td>20 (46.5%)</td>
<td>17 (43.6%)</td>
<td></td>
</tr>
<tr>
<td>Gender</td>
<td>55</td>
<td>29 (67.4%)</td>
<td>23 (59.0%)</td>
<td>0.342</td>
</tr>
<tr>
<td>Male</td>
<td>32</td>
<td>20 (62.5%)</td>
<td>12 (37.5%)</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>27</td>
<td>14 (32.6%)</td>
<td>14 (32.6%)</td>
<td></td>
</tr>
<tr>
<td>Tumor stage</td>
<td>42</td>
<td>26 (61.9%)</td>
<td>16 (38.1%)</td>
<td>0.001</td>
</tr>
<tr>
<td>T1</td>
<td>12</td>
<td>9 (20.0%)</td>
<td>3 (7.7%)</td>
<td></td>
</tr>
<tr>
<td>T2</td>
<td>38</td>
<td>30 (73.7%)</td>
<td>8 (20.5%)</td>
<td></td>
</tr>
<tr>
<td>T3</td>
<td>26</td>
<td>19 (46.2%)</td>
<td>7 (17.5%)</td>
<td></td>
</tr>
<tr>
<td>T4</td>
<td>16</td>
<td>10 (25.0%)</td>
<td>6 (15.6%)</td>
<td></td>
</tr>
<tr>
<td>Nodal status</td>
<td>55</td>
<td>22 (40.0%)</td>
<td>33 (59.9%)</td>
<td>0.008</td>
</tr>
<tr>
<td>N0</td>
<td>22</td>
<td>16 (72.7%)</td>
<td>6 (27.3%)</td>
<td></td>
</tr>
<tr>
<td>N1</td>
<td>31</td>
<td>20 (64.5%)</td>
<td>11 (35.5%)</td>
<td></td>
</tr>
<tr>
<td>N2</td>
<td>22</td>
<td>5 (22.7%)</td>
<td>17 (77.3%)</td>
<td></td>
</tr>
<tr>
<td>N3</td>
<td>7</td>
<td>2 (28.6%)</td>
<td>5 (71.4%)</td>
<td></td>
</tr>
<tr>
<td>Clinical stage</td>
<td>55</td>
<td>6 (10.9%)</td>
<td>49 (89.1%)</td>
<td>0.008</td>
</tr>
<tr>
<td>I</td>
<td>6</td>
<td>4 (66.7%)</td>
<td>2 (33.3%)</td>
<td></td>
</tr>
<tr>
<td>II</td>
<td>24</td>
<td>19 (79.2%)</td>
<td>5 (20.8%)</td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>29</td>
<td>21 (72.4%)</td>
<td>8 (27.6%)</td>
<td></td>
</tr>
<tr>
<td>IV</td>
<td>23</td>
<td>18 (78.3%)</td>
<td>5 (21.7%)</td>
<td></td>
</tr>
<tr>
<td>Distant metastasis</td>
<td>55</td>
<td>40 (72.7%)</td>
<td>15 (27.3%)</td>
<td>0.008</td>
</tr>
<tr>
<td>M0</td>
<td>63</td>
<td>48 (76.5%)</td>
<td>15 (23.5%)</td>
<td></td>
</tr>
<tr>
<td>M1</td>
<td>19</td>
<td>15 (78.9%)</td>
<td>4 (21.1%)</td>
<td></td>
</tr>
</tbody>
</table>

*Mean age; WHO, World Health Organization; Sp1 expression was determined by immunohistochemical analysis.

and their concentrations were determined by bicinchoninic acid protein concentration assay kit (Beijing Biosea Biotechnology Co. Ltd., China). Proteins (50 μg) were separated by 10% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) gels and transferred to PVDF membrane (Bio-Rad, Hercules, CA, USA). Then PVDF membrane was blocked with 3% BSA in Tris-buffer saline (TBS) containing 0.05% Tween 20 for 1 hour, followed by incubation with primary mouse monoclonal antibody against human Sp1 (1:1000) (Santa Cruz Biotechnology, Santa Cruz, CA, USA) at 37°C overnight. After washing, the PVDF membrane was incubated with second rabbit monoclonal antibody against mouse (1:1000 dilutions) conjugated to horseradish peroxidase for 2 h at room temperature. The blots were visualized by enhanced chemiluminescence (Pierce® ECL Plus Western Blotting Substrate, Pierce Biotechnology, IL, USA). GAPDH was used as an internal control.

Immunohistochemistry analysis

Paraffin sections of nasopharyngeal cancer tissues were dewaxed in xylene and rehydrated with ascending series of ethanol. Then in order for antigen retrieval, the sections were heated by 700W microwave oven for 15 min in 10 mM citrate buffer (0.1 mM citric acid, 0.1 M sodium citrate; pH 6.0). After washing with PBSTX (0.05M PBS, 0.1% Triton-X 100), sections (5 mm in thickness) were incubated with primary antibody against human Sp1 (Santa Cruz Biotechnology, Santa Cruz, CA, U.S.A) at the concentrations of 1:100 at 4°C overnight, followed by incubation with horseradish peroxidase-conjugated IgG secondary antibody (Medical Biological Laboratory, Nagoya, Japan) at 37°C for 30 min. After incubating, with complex/horseradish peroxidase (1: 200 dilution) at 37°C for 30 min, sections were visualized by immersion in dianaminobenzidine solution (10 × DAB, TBS, 30% H₂O₂). Slides were counterstained with hematoxylin before dehydration and mounting. Slides without primary antibody incubation served as a control for the background staining. The brown positive cells in section were counted, and then converted the total counts into cell densities for quantitation.

Statistical analysis

Statistical analysis was performed using commercially available software (SPSS version 14.0). All quantitative data were expressed as mean ± SEM. Student t test (unpaired, two tailed) was performed to compare the means of 2 groups. Correlations were examined using Chi-square analysis. P < 0.05 was considered statistically different.

Results

Patient characteristics and treatment outcome

Our study included 82 patients, with median age of 48 years old (range 30–75). The patient characteristics were listed in Table 1. Pre-treatment imaging was performed using magnetic resonance imaging (MRI) (n = 42, 53%), computed tomography (CT) scan (n = 32, 41%)
Sp1 expression in nasopharyngeal cancer

or both (n = 5, 6%). Radiation therapy was performed in all patients. The median follow-up time was 2.7 years (range, 1.9-3.6). At the end of the study, all patients remained alive. Fifty-eight patients acquired complete response (CR). Twenty-four patients suffered from Non-CR, including partial response (PR, n = 8), no change (NC, n = 8), or progressive disease (PD, n = 8).

Expression of Sp1 protein in vitro and in vivo by western blot analysis

In order to investigate the differential expression of Sp1 in nasopharyngeal cancer, we performed western blot analysis to determine Sp1 protein expression. CNE-1 and CNE-2 nasopharyngeal cancer cells were found to have a higher level of Sp1 protein expression as compared to normal nasopharyngeal mucosal NP69 cells (P < 0.05) (Figure 1A, 1B). We further explored the in vivo expression of Sp1 in nasopharyngeal cancer patients. Western blot was performed in tumor tissues. According to the criterion of a 1.5-fold differential expression (tumor tissue compared to the normal counterpart), there were 39 out of 82 patients (47.6%) whose tumor had Sp1 over-expression (≥ 1.5-fold), and 43 patients (52.4%) low expression (between 0.86- to 1.5-fold) (Table 1). Sp1 protein expression was determined by western blot analysis from four pairs of normal (N) and tumor (T) fresh tissues from nasopharyngeal cancer patients with Sp1 over-expression (Figure 2A, 2B).

Immunohistochemical analysis of tumor samples in nasopharyngeal cancer patients

Of 82 patient tissue sections, all were immunopositive for Sp1 protein, and immunostaining was observed to be predominantly cytoplasmic and nuclear with variable staining intensity. A total of 43 (52.4%) tissues had low Sp1 expression and 39 (47.6%) with high expression (Figure 3A-C). The results of Sp1 immunohistochemical staining were in accordance with those of western blot. Therefore, we divided nasopharyngeal cancer patients into low expression group (43 cases) and high expression group (39 cases) to investigate the associations of Sp1 expression with clinicopathological parameters or radiotherapy response in nasopharyngeal cancer patients.

Association of Sp1 immunohistochemical staining with clinicopathological parameters

The associations between Sp1 over-expression and clinicopathological parameters are summarized in Table 1. No associations were found between Sp1 over-expression and age or gender. There was significant statistical correlation between Sp1 over-expression and tumor stage, nodal status, clinical stage and distant metastasis (P < 0.05) (Table 1).

Correlation of Sp1 immunohistochemical staining with radiotherapy response

All 82 patients received radiation therapy, and fifty-eight patients acquired complete response
Sp1 expression in nasopharyngeal cancer

In this study, we used western blot method to detect the tissue sections of nasopharyngeal cancer patients, and found that the expression of Sp1 protein in cancer cell lines and tissue samples were increased compared with their normal counterparts. We further analyzed the clinicopathological significance and clinical effect of radiotherapy of Sp1 overexpression, and found that the high expression of Sp1 was related with higher tumor stage, nodal status, clinical stage and distant metastasis. Sp1 overexpression is also related with poor response of radiotherapy in nasopharyngeal cancer patients. This indicates that Sp1 protein may be one new predictive and prognostic protein for radiotherapy sensitivity in nasopharyngeal cancer.

Discussion

In this study, we found the correlation between Sp1 high expression and poor radiation therapy response in nasopharyngeal cancer patients. We therefore hypothesize that Sp1 expression is strongly associated with tumor radioresistance. Nasopharyngeal cancer is initiated and promoted by EB virus [26]. Two EB virus-encoded protein genes BHRF1 and LMP1 both contribute to radioresistance in nasopharyngeal cancer [10, 11]. This indicates that radioresistance phenotype may be acquired after the initiation of nasopharyngeal cancer. Indeed, Sp1 protein level was higher in various cancer tissues or cells than in normal tissues or cells [19-21]. Therefore, we quantitatively examined Sp1 expression levels of nasopharyngeal cancer tissues in order to determine relationship between Sp1 expression levels and various tumor stage, nodal status, clinical stage and distant metastasis of glioma tissues. In our study, higher level of Sp1 expression was related with in nasopharyngeal cancer with higher tumor stage, nodal status, clinical stage and distant metastasis (Table 1). Su et al have reported that Sp1 expression levels were elevated in metastatic NPC cell line than in non-metastatic NPC cell lines, and inhibition of Sp1 expression and activity in metastatic NPC cells resulted in reduced expression and secretion of MMP-9 and VEGF, leading to inhibition of cell migration and invasion [22]. These results suggest that MMP-9 and VEGF are target genes of Sp1 and Sp1 may promote tumor progression through MMP-9 and VEGF in the nasopharyngeal cancer patients [23]. Our study firstly investigated Sp1 expression in human nasopharyngeal cancer tissues and analyzed its expression with detailed clinicopathological parameters. Indeed, Sp1 expression plays roles in invasion, metastasis and progression of a variety of tumors, such as breast cancer and glioma [24, 25].

In this study, we found the correlation between Sp1 high expression and poor radiation therapy response in nasopharyngeal cancer patients. We therefore hypothesize that Sp1 expression is strongly associated with tumor radioresistance. Nasopharyngeal cancer is initiated and promoted by EB virus [26]. Two EB virus-encoded protein genes BHRF1 and LMP1 both contribute to radioresistance in nasopharyngeal cancer [10, 11]. This indicates that radioresistance phenotype may be acquired after the initiation of nasopharyngeal cancer. Indeed,
Sp1 expression in nasopharyngeal cancer

Radioresistance may be characteristics of cancer stem cell (CSC) and cells with radioresistance were enriched in stem cell-like population of nasopharyngeal cancer [11, 27]. Overexpression of Sp1 has been found to enhance ABCG2 expression in lung cancer cells, which plays an important role in chemotherapeutic resistance of cancer cells and phenotypic characterization of cancer stem like cells of nasopharyngeal cancer [18, 28]. Furthermore, silencing of Sp1 significantly inhibited clonogenicity and the stem-cell like phenotype of NPC cells, confirming the association between radioresistance and stem cell characteristics linked by Sp1 in nasopharyngeal cancer [29].

A variety of proteins have been found to be correlated with radioresistance of nasopharyngeal cancer, such as SOD2, 14-3-3 σ, RKIP, Y-Box-binding protein-1 and αV integrin [13-15, 30, 31]. Our finding adds a new protein to the above list. In this study, we found that Sp1-overexpression was associated with tumor progression and reduced radiosensitivity in nasopharyngeal cancer. In addition, it supports the previous report on nasopharyngeal cancer cell lines: increasing of Sp1-expression was observed in metastatic sublines. An important question for radiation oncologists is how to identify patients with locally advanced nasopharyngeal cancer who will show resistance to radiotherapy. In this regard, Sp1 may be a promising biomarker to predict radiotherapy response and assess therapeutic efficacy of radiotherapy.

Figure 3. Immunohistochemical expression of Sp1 in nasopharyngeal carcinoma tissues. Various expression levels of cytoplasmic staining of Sp1 were observed in nasopharyngeal carcinoma tissues, including low staining (A) and high staining (B) of Sp1 proteins. (C) Quantification analysis demonstrated significant difference in the quantities of Sp1 + cells in various nasopharyngeal carcinoma tissues. Data were expressed as mean ± SD. The data of each group was from three repeated experiments. A significant difference between groups is denoted by “*”. Original magnification: × 400.

Table 2. Association between Sp1 expression and radiation therapy response in nasopharyngeal cancer patients

<table>
<thead>
<tr>
<th>Therapy response</th>
<th>All cases</th>
<th>Sp1 low expression</th>
<th>Sp1 high expression</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>CR</td>
<td>48</td>
<td>37 (51.7%)</td>
<td>11 (48.3%)</td>
<td></td>
</tr>
<tr>
<td>Non-CR</td>
<td>34</td>
<td>6 (79.2%)</td>
<td>28 (20.8%)</td>
<td>&lt; 0.01</td>
</tr>
</tbody>
</table>

Abbreviations: CR, complete response; Non-CR (including PR, partial response; NC, no change; PD, progressive disease.)
Sp1 expression in nasopharyngeal cancer

nasopharyngeal cancer, thus aiding selection of individualized therapy to improve clinical outcome and reduce the risk of recurrence. The radioresistance of Sp1 may attribute to tumor invasiveness and progression in nasopharyngeal cancer patients receiving radiotherapy. Therefore, Sp1 could also be a promising target molecule for novel therapeutic strategies aimed at overcoming radioresistance of nasopharyngeal cancer. However, further studies are required to include more clinical samples to validate our findings and more detailed experiments to explore mechanisms underlying the radioresistance of Sp1 in nasopharyngeal cancer.

Disclosure of conflict of interest

None.

Address correspondence to: Dr. Ren-Sheng Wang, Department of Radiotherapy, The First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Nanning 530021, Guangxi, P.R. China. Tel: +86-771-5356509; Fax: +86-771-5356509; E-mail: wangrsgx@163.com

References


Sp1 expression in nasopharyngeal cancer


